Trial Profile
An exploratory clinical study for anlotinib combined with capecitabine in the treatment of advanced colorectal cancer
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 03 Oct 2019
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Capecitabine
- Indications Adenocarcinoma; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- 03 Oct 2019 New trial record